We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

91 hedge funds and large institutions have $49.2M invested in Karyopharm Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 30 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,266% more call options, than puts

Call options by funds: $929K | Put options by funds: $68K

0.44% less ownership

Funds ownership: 3.61% → 3.18% (-0.44%)

16% less capital invested

Capital invested by funds: $58.6M → $49.2M (-$9.41M)

20% less funds holding

Funds holding: 114 → 91 (-23)

33% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 30

71% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 31

Holders
91
Holders Change
-23
Holders Change %
-20.18%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
20
Reduced
30
Closed
31
Calls
$929K
Puts
$68K
Net Calls
+$861K
Net Calls Change
-$241K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$656K
2
EP
Eversept Partners
New York
+$465K
3
Renaissance Technologies
Renaissance Technologies
New York
+$402K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$168K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$144K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.24M
2
Jane Street
Jane Street
New York
-$1.11M
3
Goldman Sachs
Goldman Sachs
New York
-$790K
4
Millennium Management
Millennium Management
New York
-$694K
5
Barclays
Barclays
United Kingdom
-$644K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
76
Osaic Holdings
Arizona
$3.64K -$2.34K -188 -39%
QC
77
Quent Capital
New York
$2.9K – – –
PNC Financial Services Group
78
PNC Financial Services Group
Pennsylvania
$2.49K – – –
FCMT
79
Founders Capital Management (Texas)
Texas
$1.66K – – –
GSEP
80
Golden State Equity Partners
California
$1.49K +$1.49K +120 New
MLA
81
MB, Levis & Associates
Pennsylvania
$1.25K – – –
HI
82
Harbour Investments
Wisconsin
$1.08K – – –
Lazard Asset Management
83
Lazard Asset Management
New York
$1K +$1.3K +105 New
AWM
84
Activest Wealth Management
Florida
$830 – – –
Wells Fargo
85
Wells Fargo
California
$553 +$534 +43 +4,300%
AAP
86
Arax Advisory Partners
Colorado
$447 – – –
AF
87
Allworth Financial
California
$415 – – –
BGAI
88
Bruce G. Allen Investments
Colorado
$281 -$137 -11 -32%
AF
89
Advisornet Financial
Minnesota
$166 – – –
CIBC Private Wealth Group
90
CIBC Private Wealth Group
Georgia
$42 – – –
WBC
91
West Branch Capital
Massachusetts
$40 – – –
OM
92
Opaleye Management
Massachusetts
– -$1.24M -95,000 Closed
SCM
93
Superstring Capital Management
New York
– -$464K -35,632 Closed
YIH
94
Y-Intercept (HK)
Hong Kong
– -$357K -27,397 Closed
Los Angeles Capital Management
95
Los Angeles Capital Management
California
– -$307K -23,601 Closed
CC
96
Centiva Capital
New York
– -$177K -13,573 Closed
HF
97
HRT Financial
New York
– -$128K -9,836 Closed
SOW
98
State of Wyoming
Wyoming
– -$71.7K -5,512 Closed
Verition Fund Management
99
Verition Fund Management
Connecticut
– -$59.8K -4,595 Closed
SSA
100
Schonfeld Strategic Advisors
New York
– -$50K -3,840 Closed
1 2 3
4
5

KPTI Hedge Fund Activity: Q3 2024 in Review

91 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2024, worth a combined $49.2M — down 16% from $58.6M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of KPTI and 9 opened new positions — a net loss of 22 holders — while 30 trimmed existing stakes and 20 added.

The largest buyer was GSA Capital Partners, adding an estimated $656K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.24M sold.

  • 91 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2024, down from 114 in Q2 2024.
  • Funds reported $49.2M of Karyopharm Therapeutics stock for Q3 2024, down 16% quarter-over-quarter.
  • 9 funds opened new Karyopharm Therapeutics positions in Q3 2024 and 31 closed out, a net change of -22 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2024 was GSA Capital Partners, an estimated $656K added.
  • The largest Karyopharm Therapeutics seller in Q3 2024 was Opaleye Management, an estimated $1.24M sold.

Based on aggregated 13F filings for Q3 2024.